[
  {
    "ts": null,
    "headline": "Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio",
    "summary": "Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that boa",
    "url": "https://finnhub.io/api/news?id=44d7749fa68a250b618bd3b937c5f16db921d1a9cf24db06f0543465516f5baf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755548100,
      "headline": "Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio",
      "id": 136416926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that boa",
      "url": "https://finnhub.io/api/news?id=44d7749fa68a250b618bd3b937c5f16db921d1a9cf24db06f0543465516f5baf"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Flexible Capital Income Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports a 3.87% Q2 return for its Flexible Capital Income Fund. Explore how convertibles and credit picks drove gains.",
    "url": "https://finnhub.io/api/news?id=d5a663d90d1bfa07778857bf2b9899f1630dfed9ebf10c980eea07b25a17dece",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755547800,
      "headline": "Columbia Flexible Capital Income Fund Q2 2025 Commentary",
      "id": 136413799,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225316531/image_2225316531.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports a 3.87% Q2 return for its Flexible Capital Income Fund. Explore how convertibles and credit picks drove gains.\n",
      "url": "https://finnhub.io/api/news?id=d5a663d90d1bfa07778857bf2b9899f1630dfed9ebf10c980eea07b25a17dece"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Dividend Opportunity Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Opportunity Fund amid tech and energy drags. Discover how AI picks boosted returns.",
    "url": "https://finnhub.io/api/news?id=bdba0853d155b8623eb3f99a979eabcc0975400b3ed2336c660f98498d136507",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755546000,
      "headline": "Columbia Dividend Opportunity Fund Q2 2025 Commentary",
      "id": 136413620,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223505840/image_2223505840.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Opportunity Fund amid tech and energy drags. Discover how AI picks boosted returns.\n",
      "url": "https://finnhub.io/api/news?id=bdba0853d155b8623eb3f99a979eabcc0975400b3ed2336c660f98498d136507"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Dividend Income Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Income Fund amid tech and healthcare headwinds. See how quality stocks remain central.",
    "url": "https://finnhub.io/api/news?id=abdcfc7414c024b4a1ef96ab2faac9bbdfb29f442859ed22402764565c78c6b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755545400,
      "headline": "Columbia Dividend Income Fund Q2 2025 Commentary",
      "id": 136413574,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206196350/image_2206196350.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Income Fund amid tech and healthcare headwinds. See how quality stocks remain central.\n",
      "url": "https://finnhub.io/api/news?id=abdcfc7414c024b4a1ef96ab2faac9bbdfb29f442859ed22402764565c78c6b5"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=1dce70405747becac1d93beb0c58992ff089de81f402f297dc95d4150d0c51ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755522003,
      "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
      "id": 136408382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=1dce70405747becac1d93beb0c58992ff089de81f402f297dc95d4150d0c51ca"
    }
  },
  {
    "ts": null,
    "headline": "If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today",
    "summary": "You'd be sitting pretty right now.",
    "url": "https://finnhub.io/api/news?id=5ad219acb095da2cce46b77980d343ad9aa14a3f25003d8a62169726d9b82b84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755511140,
      "headline": "If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today",
      "id": 136408383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "You'd be sitting pretty right now.",
      "url": "https://finnhub.io/api/news?id=5ad219acb095da2cce46b77980d343ad9aa14a3f25003d8a62169726d9b82b84"
    }
  }
]